Tag Archives: BMSCelgene

BREAKING: Thumbs-up on $74B BMS-Celgene deal ends months of activist outrage

Bristol-Myers Squibb CEO Giovanni Caforio was less than 10 minutes into a special shareholders meeting on the company’s proposed $ 74 billion acquisition of Celgene when a broker interrupted his attempt to wrap up voting on the deal. “Are you going to address the dissenting votes?” he asked. “My family has owned tremendous quantities of… Read More »

BMS-Celgene merger chances improve with backing from proxy advisers

When it comes to Bristol-Myers Squibb’s Celgene merger, two influential proxy advisory firms have spoken—and they’re in favor of the mammoth tie-up. Institutional Shareholder Services and Glass Lewis both said Friday that they’re backing the transaction. ISS pointed to deal’s “sound” strategic rationale and cost-cutting potential, while Glass Lewis said the buy “presents the opportunity for potentially… Read More »